Table 2.

Associations of Genetically Predicted vWF, ETP, d-Dimer, FVIII, tPA, and PAI-1 With Lipids Using Mendelian Randomization With Different Methodological Approaches

ExposureOutcomeMethodNo. of SNPsβ95% CIIntercept P Value
vWF (SD)HDL cholesterolIVW160.01*0.003 to 0.02*
WM160.02*0.01 to 0.03*
MR Egger160.0250.007 to 0.040.07
Drop ABO SNP15−0.005−0.03 to 0.02
LDL cholesterolIVW160.05*0.03 to 0.06*
WM160.06*0.05 to 0.08*
MR Egger160.08*0.05 to 0.11*0.002*
Drop ABO SNP15−0.002−0.02 to 0.02
TriglyceridesIVW16−0.01−0.02 to 0.001
WM16−0.01*−0.03 to −0.004*
MR Egger16−0.02−0.04 to 0.010.50
Drop ABO SNP150.01−0.01 to 0.03
ETP (SD)HDL cholesterolWGLM50.05*0.04 to 0.07*
WM40.05*0.03 to 0.07*
MR Egger50.01–0.06 to 0.070.18
LDL cholesterolWGLM5−0.02*−0.04 to −0.01*
WM4−0.02−0.04 to 0.01
MR Egger50.03−0.01 to 0.060.004*
TriglyceridesWGLM5−0.02*−0.03 to −0.01*
WM4−0.01−0.03 to 0.005
MR Egger50.001−0.04 to 0.040.32
D-dimer (SD)HDL cholesterolIVW30.01−0.03 to 0.06
WM30.02−0.03 to 0.07
LDL cholesterolIVW30.01−0.03 to 0.06
WM30.01−0.04 to 0.07
TriglyceridesIVW30.004−0.04 to 0.05
WM3−0.003−0.05 to 0.05
FVIII (SD)HDL cholesterolIVW60.02*0.01 to 0.03*
WM60.02*0.01 to 0.03*
MR Egger60.025*0.007 to 0.04*0.61
Drop potentially pleiotropic SNPs4−0.01−0.06 to 0.05
LDL cholesterolIVW60.06*0.05 to 0.08*
WM60.07*0.05 to 0.08*
MR Egger60.08*0.07 to 0.10*0.01*
Drop potentially pleiotropic SNPs40.01−0.05 to 0.07
TriglyceridesIVW6−0.01*−0.02 to −0.002*
WM6−0.01*−0.03 to −0.003*
MR Egger6–0.02−0.05 to 0.020.84
Drop potentially pleiotropic SNPs40.04−0.03 to 0.10
tPA, ng/mLHDL cholesterolIVW30.06−0.13 to 0.26
WM30.05−0.17 to 0.28
LDL cholesterolIVW30.07−0.15 to 0.29
WM30.03−0.22 to 0.29
TriglyceridesIVW3−0.04−0.23 to 0.15
WM3−0.03−0.24 to 0.19
PAI-1, ng/mLHDL cholesterolWGLM50.03−0.04 to 0.11
WM40.10–0.02 to 0.23
MR Egger5−0.07−0.67 to 0.520.72
LDL cholesterolWGLM50.06−0.02 to 0.14
WM40.01−0.10 to 0.12
MR Egger5–0.07−0.49 to 0.360.55
TriglyceridesWGLM50.100.03 to 0.18
WM40.110.001 to 0.22
MR Egger50.14−0.45 to 0.720.92
  • CI indicates confidence interval; ETP, endogenous thrombin potential; FVIII, factor VIII; HDL, high-density lipoprotein; IVW, inverse variance weighting; LDL, low-density lipoprotein; PAI, plasminogen activator inhibitor; tPA, tissue-type plasminogen activator; vWF, von Willebrand factor; WGLM, weighted generalized linear regression model; and WM, weighted median method.

  • * p value<0.05.